Aktienanalyse zu Century Therapeutics Inc (IPSC)IPSCCentury Therapeutics Inc

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Century Therapeutics Inc (IPSC) is a good buy right now due to its recent earnings beat with a GAAP EPS of -$0.11, which exceeded expectations by $0.06, indicating improving financial performance. Additionally, the company has a strong cash position of $217 million, providing a runway into Q1 2029, which enhances its financial stability. The current price of $1.48 is significantly below the analyst price target of $8, suggesting a potential upside of over 440%. However, the main risk is the negative earnings trend, with a projected EPS of -0.12 for the next earnings report on November 12, 2026.